Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared with Docetaxel in Patients with NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance

Next Previous
Search
Trial Profile

A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared with Docetaxel in Patients with NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Cemiplimab (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Nivolumab (Primary) ; Olvimulogene nanivacirepvec (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms VIRO-25
  • Sponsors Genelux Corporation

    • Most Recent Events

    • 14 Nov 2024 According to a Genelux Corporation media release, data from this Phase 2 trial in NSCLC expected by mid-2025.
    • 14 Nov 2024 According to a Genelux Corporation media release, this study designed based on earlier clinical results, including Olvi-Vec demonstrating (i) positive outcomes in patients with primary or metastatic lung cancer when delivered intravenously and (ii) clinical reversal of platinum resistance and refractoriness in a Phase 2 trial in platinum-resistant/refractory ovarian cancer (PRROC).
    • 22 Oct 2024 According to a Genelux Corporation media release, first patient has been dosed in this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top